Vantiva S.A. (EPA:VANTI)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	-282	-285	151	-140	-211
Depreciation & Amortization	-	101	80	135	139	261
Loss (Gain) From Sale of Assets	-	-7	-	3	-23	-14
Asset Writedown & Restructuring Costs	-	5	5	5	3	-70
Loss (Gain) From Sale of Investments	-	1	25	-	-	-
Loss (Gain) on Equity Investments	-	-	-	311	-	-
Other Operating Activities	-	115	187	-576	115	49
Change in Other Net Operating Assets	-	103	-19	57	-98	-101
Operating Cash Flow	-	26	49	8	103	-109
Operating Cash Flow Growth	-	-46.94%	512.50%	-92.23%	-	-
Capital Expenditures	-	-12	-16	-36	-33	-33
Sale of Property, Plant & Equipment	-	-	-	2	-	-
Cash Acquisitions	-	-	-	-	-	-3
Sale (Purchase) of Intangibles	-	-62	-44	-47	-36	-71
Investment in Securities	-	-	-10	-	-	7
Other Investing Activities	-	5	-69	42	-7	-33
Investing Cash Flow	-	-69	-139	-39	-76	-133
Long-Term Debt Issued	-	54	83	356	-	760
Long-Term Debt Repaid	-	-98	-12	-1,160	-29	-243
Net Debt Issued (Repaid)	-	-44	71	-804	-29	517
Issuance of Common Stock	-	-	-	284	-	60
Other Financing Activities	-	-23	-29	546	-41	-55
Financing Cash Flow	-	-67	42	26	-70	522
Foreign Exchange Rate Adjustments	-	-	-6	-25	16	-16
Miscellaneous Cash Flow Adjustments	-	7	21	1	-107	1
Net Cash Flow	-	-103	-33	-29	-134	265
Free Cash Flow	-	14	33	-28	70	-142
Free Cash Flow Growth	-	-57.58%	-	-	-	-
Free Cash Flow Margin	-	0.75%	2.11%	-1.01%	3.11%	-4.72%
Free Cash Flow Per Share	-	0.03	0.09	-0.10	0.30	-1.93
Cash Interest Paid	-	47	30	65	54	51
Cash Income Tax Paid	-	18	13	19	14	12
Levered Free Cash Flow	-	107.65	-70.48	-22.03	-64.13	-52.25
Unlevered Free Cash Flow	-	153.9	-29.85	82.98	8.38	-1
Change in Net Working Capital	-	-116	57	-19	69	93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.